Logo image
Safety, efficacy and effectiveness of delabeling in patients with multiple drug allergy labels
Journal article   Open access   Peer reviewed

Safety, efficacy and effectiveness of delabeling in patients with multiple drug allergy labels

C. Vethody, R. Yu, J.M. Keck, M.K. Onasch, C.A. Stone and E.J. Phillips
The Journal of Allergy and Clinical Immunology: In Practice, Vol.9(2), pp.922-928
2020
pdf
multiple drug allergy.pdfDownloadView
Author’s Version Open Access
url
Link to Published Version *Subscription may be requiredView

Abstract

Background Patients with multiple drug allergy labels (MDAL) present a challenging barrier to patient care. Objective To assess the efficacy, safety and effectiveness of removing MDAL in a single clinic visit. Methods Retrospective chart review was performed from October 1, 2014 to October 31, 2018 on MDAL patients who had electronic health record (EHR) allergy label to two or more drug and who were delabeled to ≥1 drug.. Our primary outcome was the number of allergy labels tested and removed, at a single or multiple visits. Post-visit surveys were administered to patients, their pharmacies and primary care physicians (PCP) for patients delabeled following an EHR transition from November 2, 2017 to October 31st 2018 (n=184). Results Among 536 patients meeting inclusion criteria, 916/943 (97.1%) of tested allergy labels were removed from the EHR . Most patients 461/536 (86.0%) were tested, challenged and delabeled in a single visit, to ≥ 1 drug, although 134/536 (25%) still had evidence of > 1 label at one year. In surveys, 90/171 (52.6%) of responding pharmacies and 122/168 (72.6%) of PCPs contacted had removed drug labels from the EHR as a result of the recommendations from the patient’s drug allergy evaluation. Overall, 91/142 (64.1%) of MDAL patient survey respondents were willing to take the drugs to which they had been delabeled. Conclusions MDAL patients can be safely delabeled to multiple drugs in one visit, however effectiveness barriers were identified. Reinforcement of drug allergy label removal information to patients, pharmacies and primary care providers presents a targeted area for improvement.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

53 File views/ downloads
112 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.265 Dermatology - Skin Allergies
1.265.1140 Drug Hypersensitivity
Web Of Science research areas
Allergy
Immunology
ESI research areas
Clinical Medicine
Logo image